HIF1A and renal cell carcinoma: Conversely, PHD inhibitors that inhibit and stabilize HIF-1α degradation have been employed as pharmacological agents for renal anemia [100], while HIF-2α inhibitors have been utilized in the treatment of renal cell carcinoma [101].